Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted with diagnosis of upper gastrointestinal bleeding aged between 18 and 80~* Endoscopic confirmation of a bleeding duodenal or gastric ulcer to which endoscopic control has been obtained~* Absence of H. pylori infection~* Informed written consent~Exclusion Criteria:~* Known incompatibility to the study drugs;~* Known incompatibility and hypersensitivity to proton pump inhibitor~* H. pylori infection~* Recent H2RA or PPI use (within last 4 weeks)~* Concomitant use of medications that may interfere gastric acid secretion or motility (e.g. anticholinergic, metoclopramide, domperidone)~* Pregnancy or lactation;~* Non-compliance e.g. mental subordination~* Nasopharyngeal or oropharyngeal pathology that would prevent passage of a nasal catheter~* Significant liver disease as PPI is metabolized by the cytochrome P-450 system~* Previous gastric surgery~* Chronic Aspirin user~* Presence of esophageal/ gastric varices~* Moribund patients, terminal malignancy \& patients with severe renal disease~* Patient unable to give written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV Nexium (Type: ACTIVE_COMPARATOR): Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
- Oral Nexium (Type: ACTIVE_COMPARATOR): Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).